-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100

Benzinga·12/15/2025 20:45:28
Listen to the news
Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target from $85 to $100.